

Data summary					
Access to medicines	2003	2004	2005	2006	2007
Number of countries supplied with GSK preferentially priced ARVs <sup>1</sup>	56	57	56	51	31
Number of <i>Combivir</i> and <i>Epivir</i> tablets shipped (millions) <sup>1</sup>	16.2	66.4	126.3	86.3	85.0
Number of generic ARVs supplied under licence from GSK (millions)	–	–	–	120	183.0
GSK <i>Combivir</i> not-for-profit price (\$ per day) <sup>2</sup>	1.7	0.65	0.65	0.65	0.54
Voluntary licences granted to generic manufacturers for GSK ARVs (cumulative total) <sup>3</sup>	–	6	7	9	9
Value of products donated through GSK Patient Assistance Program in the US (£ millions)	125	203	255	200	194
Research and Development					
Expenditure on R&D (£ billions)	2.8	2.9	3.1	3.5	3.3
GSK animal research facilities accredited by the Association for Assessment and Accreditation of Laboratory Animal Care <sup>4</sup>	7	10	10	10	10
Number of trials published on the GSK Clinical Trial Register (cumulative total)	–	143	2,125	2,760	3,089
Ethical conduct					
Number of employees completing certification to the GSK Code of Conduct	9,000	9,600	>12,000	>12,000	>14,000
Number of contacts through our ethics compliance channels <sup>5</sup>	–	2,580	3,644	5,363	5,265
Employment					
Women in management grades (%)	34	35	35	36	37
Ethnic diversity – people of colour (US, %)	19.5	19.5	19.6	19.8	20.1
Ethnic diversity – ethnic minorities (UK, %)	–	14.8	14.9	18.3	19.1
Lost time injury and illness rate (cases per 100,000 hours worked)	0.30	0.30	0.30	0.33	0.33
Environment					
Number of contract manufacturers audited	28	35	41	36	55
Energy consumption (million gigajoules)	20	19	20	19	19
Water consumption (million cubic metres)	23	21	22	22	21
Ozone depletion potential from metered dose inhalers (tonnes CFC-11 equivalent) <sup>6</sup>	782	464	273	186	136
Ozone depletion potential from production (tonnes CFC-11 equivalent)	72	59	51	33	15
Ozone depletion potential from refrigeration and other ancillary uses (tonnes CFC-11 equivalent)	3	3	3	1	1
Volatile organic compound emissions (thousand tonnes)	6	5	5	4	4
Global warming potential from energy sources (thousand tonnes CO <sub>2</sub> equivalent)	1,756	1,667	1,716	1,688	1,667
Hazardous waste disposed (thousand tonnes)	58	71	65	70	68
Community investment					
Total community investment expenditure (£ millions)	338	328	380	302	282
Value of humanitarian product donations, including albendazole (£ millions)	116	57	41	38	30
Number of albendazole tablets donated for prevention of lymphatic filariasis (millions)	94	67	136	155	150

<sup>1</sup> Includes ARVs sold at not-for-profit and discounted prices. We are unable to collect data for the number of patients treated.

<sup>2</sup> Includes freight and delivery costs. The Médecins Sans Frontières pricing report lists the average cost of generic equivalents.

<sup>3</sup> Only eight are currently in force.

<sup>4</sup> This covers approximately 92 per cent of animals used in GSK facilities.

<sup>5</sup> Includes contacts with line managers, compliance officers, our confidential Integrity Helplines or offsite post office box (in the US).

<sup>6</sup> 2002 to 2004 data do not include inhalers made in Asia.

## **Global Compact index**

## **GRI index**

### **Trademarks**

Brand names appearing in italics throughout this publication are trademarks either owned by and/or licensed to GSK or associated companies.